Year: 2017
Type: review
Abstract: Biomarker research in Parkinson's disease (PD) has long been dominated by measuring dopamine metabolites or alpha-synuclein in cerebrospinal fluid. However, these markers do not allow early detection, precise prognosis or monitoring of disease progression. Moreover, PD is now considered a multifactorial disease, which requires a more precise diagnosis and personalized medication to obtain optimal outcome. In recent years, advanced metabolite profiling of body fluids like serum/plasma, CSF or urine, known as "metabolomics", has become a powerful and promising tool to identify novel biomarkers or "metabolic fingerprints" characteristic for PD at various stages of disease. In this review, we discuss metabolite profiling in clinical and experimental PD. We briefly review the use of different analytical platforms and methodologies and discuss the obtained results, the involved metabolic pathways, the potential as a biomarker and the significance of understanding the pathophysiology of PD. Many of the studies report alterations in alanine, branched-chain amino acids and fatty acid metabolism, all pointing to mitochondrial dysfunction in PD. Aromatic amino acids (phenylalanine, tyrosine, tryptophan) and purine metabolism (uric acid) are also altered in most metabolite profiling studies in PD.
Source: Metabolites
Language: English
Subfield: Clinical Neurology
Field: Medicine
Domain: Health Sciences
Keywords: Parkinson's disease, metabolomics, biomarkers, metabolic fingerprint, branched-chain amino acids, alanine metabolism, fatty acid metabolism, mitochondrial dysfunction, aromatic amino acids, purine metabolism, uric acid, cerebrospinal fluid, urinary metabolites, disease progression monitoring
Open Access status: gold
Estimated APC paid: $3,258
Funders: Villum Fonden, Jascha Fonden
Award: G7593214324
OpenAlex ID: W2742319332
